The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected to pose little risk to the rare disease community, including to patients with compromised immune systems or those participating in gene therapy studies.
That was the message of a recent webinar, hosted by the National Organization for Rare Disorders (NORD), in which officials from the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) addressed concerns from the rare disease community regarding the newly available COVID-19 vaccines.
